Followers | 2454 |
Posts | 79994 |
Boards Moderated | 0 |
Alias Born | 06/15/2009 |
Friday, November 03, 2023 10:10:17 AM
Recent VIRI News
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/18/2024 02:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/21/2024 02:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2024 01:15:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2024 12:15:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 01:25:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/17/2024 08:30:26 PM
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 10/15/2024 08:19:38 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/07/2024 12:06:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2024 12:02:34 PM
- Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”) • GlobeNewswire Inc. • 10/07/2024 11:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 02:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 01:30:13 PM
- Virios Therapeutics Announces Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 01:15:00 PM
- Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 • GlobeNewswire Inc. • 08/01/2024 01:41:56 PM
- Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center • GlobeNewswire Inc. • 07/23/2024 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 01:15:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 01:15:20 PM
- Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/22/2024 05:30:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/20/2024 08:05:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 01:28:00 PM
- Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/20/2024 12:53:09 AM
- Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study • GlobeNewswire Inc. • 05/17/2024 08:10:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 05/17/2024 08:01:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 02:30:38 PM
FEATURED Cannabix and AlcoPro Enter MOU for Marijuana Breathalyzer Marketing • Jan 24, 2025 8:49 AM
UC Asset Announces Plan of Secondary Public Offering via Reg A • UCASU • Jan 23, 2025 9:30 AM
Luke Plants Featured in U.S. Department of the Interior Report to Congress on Strategic Review of National Orphan Well Program • ZEFIF • Jan 21, 2025 10:51 AM
North Bay Resources Acquires 70% Interest in the Bishop Gold Mill, Inyo County, California • NBRI • Jan 21, 2025 9:26 AM
HealthLynked Unveils Release of ARi: A Revolutionary AI-Powered Healthcare Assistant • HLYK • Jan 21, 2025 8:00 AM
Good Gaming Inc. Announces ViaOne Services' Intent to Purchase Up to 10% of Its Common Shares in the Open Market • GMER • Jan 16, 2025 8:30 AM